

The House has passed more than 40 bills that would address our struggling economy and help create jobs. These bills are now sitting in the Senate while that body debates whether or not to gut the First Amendment.

Maybe if the Senators acted on some of these House-passed bills they wouldn't have to spend so much time worrying about what people are saying about them.

GOSPEL MUSIC HISTORY MONTH

(Ms. JACKSON LEE asked and was given permission to address the House for 1 minute.)

Ms. JACKSON LEE. Mr. Speaker, sometimes we have the opportunity to come and to share some of the joys of America. This month is gospel music history month, and I am delighted to be able to say that we are celebrating the history of gospel music.

In 2008, former Senator Blanche Lincoln and myself introduced a resolution to name September gospel music heritage month, and we are doing that to be able to reflect upon the writers and singers and musicians of gospel music throughout the country, in different areas around, in Appalachia and the Deep South and Midwest and the Far West and the east coast where people sing it in their own way, where soldiers sing the music and people sing it for comfort and joy.

Tonight at the Kennedy Center, we will be honoring the former Senator, Blanche Lincoln, of Arkansas with Yolanda Adams and Kirk Franklin. These are individuals who represent a long trend of history in gospel music, but the real idea is to say that America is such a free and wonderful country that we can reflect upon the goodness of so many, singing songs of joy and praise, without the degradation and the trepidation of government interference, gospel music heritage, simply to say thank you—thank you for the music over the years.

From the 1700s and 1800s and 1900s, through war and peace, gospel music has been a comfort to many Americans. I am delighted to celebrate and thank all of those who have contributed to the great history of America, gospel music history month.

TRIBUTE TO KEVIE NILAND ON HER RETIREMENT

(Mr. VAN HOLLEN asked and was given permission to address the House for 1 minute.)

Mr. VAN HOLLEN. Mr. Speaker, I rise today to recognize the career of my constituent Kevie Niland who recently retired after 34 years of service to the United States House of Representatives.

Kevie came to the House in 1980 to be a constituent service coordinator for Congressman Miller, beginning a long career of service to the American people. She later moved to the Clerk's office, starting as an administrative as-

sistant before becoming Assistant Clerk to the Official Reporters in 1995. Four years later, she was named Reading Clerk, and then, in 2009, she took the office of Deputy Chief of Legislative Operations for the House of Representatives.

Kevie served under seven Speakers of the House, from Tip O'Neill to JOHN BOEHNER, and has had a front seat for many historic and spirited debates in this Chamber. I have encouraged her to write a book, but she has responded, "No one would believe it." Her extraordinary efforts to record and support the work of the House makes our actions open and transparent to all American citizens and holds each of us accountable to the constituents we serve.

I know Kevie plans to take a well-deserved vacation, but I expect that she will continue to find ways to serve her community. I know we all feel very lucky to have benefited from her work here in the House.

Mr. Speaker, I ask my colleagues to join me in congratulating Kevie Niland on her outstanding and productive service to this body and to our country and wish her the very best in her well-earned retirement.

COMMUNICATION FROM THE CLERK OF THE HOUSE

The SPEAKER pro tempore laid before the House the following communication from the Clerk of the House of Representatives:

OFFICE OF THE CLERK,
HOUSE OF REPRESENTATIVES,
Washington, DC, September 11, 2014.

Hon. JOHN A. BOEHNER,
Speaker, House of Representatives,
Washington, DC.

DEAR MR. SPEAKER: Pursuant to the permission granted in Clause 2(h) of Rule II of the Rules of the U.S. House of Representatives, the Clerk received the following message from the Secretary of the Senate on September 11, 2014 at 4:44 p.m.:

That the Senate passed S. 2258.
That the Senate passed without amendment H.R. 4197.

With best wishes, I am
Sincerely,

KAREN L. HAAS.

RECESS

The SPEAKER pro tempore. Pursuant to clause 12(a) of rule I, the Chair declares the House in recess until approximately 4 p.m. today.

Accordingly (at 2 o'clock and 9 minutes p.m.), the House stood in recess.

□ 1600

AFTER RECESS

The recess having expired, the House was called to order by the Speaker pro tempore (Mr. COLLINS of New York) at 4 p.m.

ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, the Chair

will postpone further proceedings today on motions to suspend the rules on which a recorded vote or the yeas and nays are ordered, or on which the vote incurs objection under clause 6 of rule XX.

Record votes on postponed questions will be taken later.

DESIGNER ANABOLIC STEROID CONTROL ACT OF 2014

Mr. PITTS. Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 4771) to amend the Controlled Substances Act to more effectively regulate anabolic steroids, as amended.

The Clerk read the title of the bill.

The text of the bill is as follows:

H.R. 4771

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the "Designer Anabolic Steroid Control Act of 2014".

SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT.

(a) DEFINITIONS.—Section 102(41) of the Controlled Substances Act (21 U.S.C. 802(41)) is amended—

(1) in subparagraph (A)—

(A) in clause (xlix), by striking "and" at the end;

(B) by redesignating clause (xlix) as clause (lxxv); and

(C) by inserting after clause (xlix) the following:

"(1) 5 α -Androstan-3,6,17-trione;
"(li) 6-bromo-androstan-3,17-dione;
"(lii) 6-bromo-androsta-1,4-diene-3,17-dione;
"(liii) 4-chloro-17 α -methyl-androsta-1,4-diene-3,17 β -diol;
"(liv) 4-chloro-17 α -methyl-androst-4-ene-3 β ,17 β -diol;

"(lv) 4-chloro-17 α -methyl-17 β -hydroxy-androst-4-en-3-one;

"(lvi) 4-chloro-17 α -methyl-17 β -hydroxy-androst-4-ene-3,11-dione;

"(lvii) 4-chloro-17 α -methyl-androsta-1,4-diene-3,17 β -diol;

"(lviii) 2 α ,17 α -dimethyl-17 β -hydroxy-5 α -androstan-3-one;

"(lix) 2 α ,17 α -dimethyl-17 β -hydroxy-5 β -androstan-3-one;

"(lx) 2 α ,3 α -epithio-17 α -methyl-5 α -androstan-17 β -ol;

"(lxi) [3,2-c]-furazan-5 α -androstan-17 β -ol;

"(lxii) 3 β -hydroxy-estra-4,9,11-trien-17-one;

"(lxiii) 17 α -methyl-androst-2-ene-3,17 β -diol;

"(lxiv) 17 α -methyl-androsta-1,4-diene-3,17 β -diol;

"(lxv) Estra-4,9,11-triene-3,17-dione;

"(lxvi) 18 α -Homo-3-hydroxy-estra-2,5(10)-dien-17-one;

"(lxvii) 6 α -Methyl-androst-4-ene-3,17-dione;

"(lxviii) 17 α -Methyl-androstan-3-hydroxyimine-17 β -ol;

"(lxix) 17 α -Methyl-5 α -androstan-17 β -ol;

"(lxx) 17 β -Hydroxy-androstano[2,3-d]isoxazole;

"(lxxi) 17 β -Hydroxy-androstano[3,2-c]isoxazole;

"(lxxii) 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5 α -androstan-17 β -ol;

"(lxxiii) [3,2-c]pyrazole-androst-4-en-17 β -ol;

"(lxxiv) [3,2-c]pyrazole-5 α -androstan-17 β -ol; and"; and

(2) by adding at the end the following:

"(C)(i) Subject to clause (ii), a drug or hormonal substance (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that is not listed in subparagraph (A) and is derived from, or has

a chemical structure substantially similar to, 1 or more anabolic steroids listed in subparagraph (A) shall be considered to be an anabolic steroid for purposes of this Act if—

“(I) the drug or substance has been created or manufactured with the intent of producing a drug or other substance that either—

“(aa) promotes muscle growth; or

“(bb) otherwise causes a pharmacological effect similar to that of testosterone; or

“(II) the drug or substance has been, or is intended to be, marketed or otherwise promoted in any manner suggesting that consuming it will promote muscle growth or any other pharmacological effect similar to that of testosterone.

“(ii) A substance shall not be considered to be a drug or hormonal substance for purposes of this subparagraph if it—

“(I) is—

“(aa) an herb or other botanical;

“(bb) a concentrate, metabolite, or extract of, or a constituent isolated directly from, an herb or other botanical; or

“(cc) a combination of 2 or more substances described in item (aa) or (bb);

“(II) is a dietary ingredient for purposes of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.); and

“(III) is not anabolic or androgenic.

“(iii) In accordance with section 515(a), any person claiming the benefit of an exemption or exception under clause (ii) shall bear the burden of going forward with the evidence with respect to such exemption or exception.”.

(b) CLASSIFICATION AUTHORITY.—Section 201 of the Controlled Substances Act (21 U.S.C. 811) is amended by adding at the end the following:

“(i) TEMPORARY AND PERMANENT SCHEDULING OF RECENTLY EMERGED ANABOLIC STEROIDS.—

“(1) The Attorney General may issue a temporary order adding a drug or other substance to the definition of anabolic steroids if the Attorney General finds that—

“(A) the drug or other substance satisfies the criteria for being considered an anabolic steroid under section 102(41) but is not listed in that section or by regulation of the Attorney General as being an anabolic steroid; and

“(B) adding such drug or other substance to the definition of anabolic steroids will assist in preventing abuse or misuse of the drug or other substance.

“(2) An order issued under paragraph (1) shall not take effect until 30 days after the date of the publication by the Attorney General of a notice in the Federal Register of the intention to issue such order and the grounds upon which such order is to be issued. The order shall expire not later than 24 months after the date it becomes effective, except that the Attorney General may, during the pendency of proceedings under paragraph (6), extend the temporary scheduling order for up to 6 months.

“(3) The Attorney General shall transmit notice of an order proposed to be issued under paragraph (1) to the Secretary of Health and Human Services. In issuing an order under paragraph (1), the Attorney General shall take into consideration any comments submitted by the Secretary in response to a notice transmitted pursuant to this paragraph.

“(4) A temporary scheduling order issued under paragraph (1) shall be vacated upon the issuance of a permanent scheduling order under paragraph (6).

“(5) An order issued under paragraph (1) is not subject to judicial review.

“(6) The Attorney General may, by rule, issue a permanent order adding a drug or other substance to the definition of anabolic steroids if such drug or other substance sat-

isfies the criteria for being considered an anabolic steroid under section 102(41). Such rulemaking may be commenced simultaneously with the issuance of the temporary order issued under paragraph (1).”.

SEC. 3. LABELING REQUIREMENTS.

(a) IN GENERAL.—Section 305 of the Controlled Substances Act (21 U.S.C. 825) is amended by adding at the end the following:

“(e) FALSE LABELING OF ANABOLIC STEROIDS.—

“(1) It shall be unlawful to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, an anabolic steroid or product containing an anabolic steroid, unless the steroid or product bears a label clearly identifying an anabolic steroid or product containing an anabolic steroid by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC).

“(2)(A) A product described in subparagraph (B) is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this subsection if such product is labeled in the manner required under the Federal Food, Drug, and Cosmetic Act.

“(B) A product is described in this subparagraph if the product—

“(i) is the subject of an approved application as described in section 505(b) or (j) of the Federal Food, Drug, and Cosmetic Act; or

“(ii) is exempt from the provisions of section 505 of such Act relating to new drugs because—

“(I) it is intended solely for investigational use as described in section 505(i) of such Act; and

“(II) such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application.”.

(b) CLARIFICATION TO IMPORT AND EXPORT STATUTE.—Section 1010 of the Controlled Substances Import and Export Act (21 U.S.C. 960) is amended, in subsection (a)(1), by inserting “305,” before “1002”.

(c) CIVIL PENALTIES.—Section 402 of the Controlled Substances Act (21 U.S.C. 842) is amended—

(1) in subsection (a)—

(A) in paragraph (14), by striking “or” at the end;

(B) in paragraph (15), by striking the period at the end and inserting “; or”; and

(C) by inserting, after paragraph (15), the following:

“(16) to violate subsection (e) of section 825 of this title.”; and

(2) in subsection (c)(1)—

(A) by inserting, in subparagraph (A), after “subparagraph (B)” the following: “; (C), or (D)”; and

(B) by inserting after subparagraph (B) the following:

“(C) In the case of a violation of paragraph (16) of subsection (a) of this section by an importer, exporter, manufacturer, or distributor (other than as provided in subparagraph (D)), up to \$500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute, in violation of paragraph (16) of subsection (a).

“(D) In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of paragraph (16) of subsection (a) of this section at the retail level, up to \$1000 per violation. For purposes of this paragraph, the term ‘at the retail level’ refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that

is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of such paragraph (16) of subsection (a) shall be considered a separate violation.”.

SEC. 4. IDENTIFICATION AND PUBLICATION OF LIST OF PRODUCTS CONTAINING ANABOLIC STEROIDS.

(a) IN GENERAL.—The Attorney General may, in the Attorney General’s discretion, collect data and analyze products to determine whether they contain anabolic steroids and are properly labeled in accordance with this Act and the amendments made by this Act. The Attorney General may publish in the Federal Register or on the website of the Drug Enforcement Administration a list of products which the Attorney General has determined, based on substantial evidence, contain an anabolic steroid and are not labeled in accordance with this Act and the amendments made by this Act.

(b) ABSENCE FROM LIST.—The absence of a product from the list referred to in subsection (a) shall not constitute evidence that the product does not contain an anabolic steroid.

The SPEAKER pro tempore. Pursuant to the rule, the gentleman from Pennsylvania (Mr. PITTS) and the gentlewoman from the Virginia Islands (Mrs. CHRISTENSEN) each will control 20 minutes.

The Chair recognizes the gentleman from Pennsylvania.

GENERAL LEAVE

Mr. PITTS. Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days in which to revise and extend their remarks and to insert extraneous materials into the RECORD on the bill.

The SPEAKER pro tempore. Is there objection to the request of the gentleman from Pennsylvania?

There was no objection.

Mr. PITTS. Mr. Speaker, I yield myself such time as I may consume.

Mr. Speaker, the Health Subcommittee ranking member, FRANK PALLONE, and I introduced H.R. 4771, the Designer Anabolic Steroid Control Act, DASCA, to end a loophole that allows designer anabolic steroids to easily be found online, in gyms, and even in retail stores.

When taken by consumers, designer steroids, which are class III controlled substances, can cause serious medical harm, including liver injury, increased risk of heart attack, and stroke. They may also lead to aggression, hostility, and addiction.

Designer steroids are produced by reverse engineering existing illegal steroids and then slightly modifying their chemical composition so the resulting product is not on the DEA’s list of controlled substances.

DASCA will help protect consumers from these harmful products by giving the DEA the tools and authority to properly classify designer steroids as controlled substances and increase criminal penalties for importing, manufacturing, or distributing them under false labels.

DASCA would:

Immediately place a number of known designer anabolic steroids on the list of controlled substances;

Grant the DEA authority to temporarily schedule new designer steroids on the controlled substances list for 24 months, with the possibility of a 6-month extension so that if bad actors develop new variations, these products can be removed from the market immediately;

Create new penalties for importing, manufacturing, or distributing anabolic steroids under false labels; and

Authorize the Attorney General to publish a list of products containing an anabolic steroid that are not properly labeled.

DASCA is supported by the American Herbal Products Association, AHPA; the Consumer Healthcare Products Association, CHPA; the Council for Responsible Nutrition, CRN; the Natural Products Association, NPA; and the United Natural Products Alliance, UNPA.

I would urge all Members to support this critical piece of legislation. It is bipartisan. I reserve the balance of my time.

Mrs. CHRISTENSEN. Mr. Speaker, I yield myself such time as I may consume.

Mr. Speaker, I rise in support of H.R. 4771, the Designer Anabolic Steroid Control Act of 2014.

H.R. 4771 would amend the Controlled Substances Act to expand the definition of "anabolic steroids" to include 25 additional chemicals, thereby facilitating their control by the Drug Enforcement Agency. The CSA contains a list of chemicals defined as anabolic steroids. However, chemists, as you have heard, are able to design around the list, creating new anabolic steroids that are not on the CSA list. The DEA, therefore, has a more difficult time making enforcement actions against people using them.

The bill will also make it easier for the Drug Enforcement Agency to add subsequent designer chemicals to the list of anabolic steroids and increases civil and criminal penalties for offenses pertaining to anabolic steroids.

Anabolic steroids are synthetic variants of the male sex hormone testosterone. They have a number of therapeutic uses but are also used by muscle builders and athletes to improve performance. Long-term or high-dosage use can cause adverse health effects, including damage to the liver and heart, and testicular atrophy.

H.R. 4771 will go a long way toward removing dangerous steroids from the market. We have seen the harm these drugs have caused, particularly in our youth and in professional sports, particularly baseball. The bill will give DEA an important tool to fight the use of hard-to-detect designer steroids.

I want to commend Chairman JOE PITTS and Ranking Member FRANK PALLONE for their sponsorship of this bipartisan legislation.

I urge my colleagues to join me in supporting today's legislation, and I yield back the balance of my time.

Mr. PITTS. Mr. Speaker, I urge all Members to support this bipartisan leg-

islation, and I yield back the balance of my time.

Mr. WAXMAN. Mr. Speaker, I rise to support passage of the Designer Anabolic Steroid Control Act of 2014.

This legislation will amend the Controlled Substances Act, the CSA, to include 25 additional chemicals as anabolic steroids. It also will make it easier for the Drug Enforcement Agency, DEA, to add additional chemicals to the CSA list of anabolic steroids. And it increases civil and criminal penalties for offenses pertaining to anabolic steroids.

Anabolic steroids have legitimate therapeutic uses, but they also can cause severe adverse effects when used inappropriately. I have been concerned for many years about the harms they have caused in young people and professional athletes, who take them to improve athletic and body building performance.

One challenge our nation has faced in stopping steroid abuse is that chemists are continually finding ways to design new versions of these drugs that can escape detection or evade the law. This bill helps address this problem. It will give DEA new tools to control the abuse of designer steroids and will help get them off the market.

I commend Chairman JOE PITTS and Ranking Member FRANK PALLONE for their sponsorship of this bipartisan legislation.

I urge all members to support it.

The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Pennsylvania (Mr. PITTS) that the House suspend the rules and pass the bill, H.R. 4771, as amended.

The question was taken; and (two-thirds being in the affirmative) the rules were suspended and the bill, as amended, was passed.

A motion to reconsider was laid on the table.

EMERGENCY MEDICAL SERVICES FOR CHILDREN REAUTHORIZATION ACT OF 2014

Mr. PITTS. Mr. Speaker, I move to suspend the rules and pass the bill (S. 2154) to amend the Public Health Service Act to reauthorize the Emergency Medical Services for Children Program.

The Clerk read the title of the bill.

The text of the bill is as follows:

S. 2154

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the "Emergency Medical Services for Children Reauthorization Act of 2014".

SEC. 2. AUTHORIZATION OF APPROPRIATIONS.

Section 1910(d) of the Public Health Service Act (42 U.S.C. 300w-9(d)) is amended—

(1) by striking "and \$30,387,656" and inserting "\$30,387,656"; and

(2) by inserting before the period "and \$20,213,000 for each of fiscal years 2015 through 2019".

The SPEAKER pro tempore. Pursuant to the rule, the gentleman from Pennsylvania (Mr. PITTS) and the gentlewoman from the Virgin Islands (Mrs. CHRISTENSEN) each will control 20 minutes.

The Chair recognizes the gentleman from Pennsylvania.

GENERAL LEAVE

Mr. PITTS. Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days in which to revise and extend their remarks and to insert extraneous materials into the RECORD on the bill.

The SPEAKER pro tempore. Is there objection to the request of the gentleman from Pennsylvania?

There was no objection.

Mr. PITTS. Mr. Speaker, I yield myself such time as I may consume.

Mr. Speaker, I rise today in support of S. 2154, the Emergency Medical Services for Children Reauthorization Act of 2014, introduced by Senator CASEY of Pennsylvania and Senator HATCH of Utah and championed in the House by Mr. MATHESON of Utah and Mr. KING of New York.

A child's health care necessities are not the same as their parents. Children have special health care needs, and the emergency and trauma care system has been slow to develop an adequate response. Fragmentation and poor coordination among pre-hospital services, hospitals, and public health are problems that involve emergency services in general. The gravity of the problem is worse for children when hospitals lack the appropriate medical personnel, pediatric supplies, or transfer agreements that lead to better care within the "golden hour," when chances for survival are higher.

In 1984, Congress passed the Emergency Medical Services for Children, EMSC, as part of the Preventive Health Amendments of 1984. The program was last reauthorized in 2010 and aims to reduce child and youth mortality and morbidity caused by severe illness or trauma. EMSC was designed to ensure that pediatric service is well integrated into an emergency medical service system and that the entire spectrum of emergency services is provided to children and adolescents, as well as adults.

The bill is almost identical to H.R. 4290, which the House passed last week. Voting for S. 2154 would send the bill to the President so we can continue this important program that helps our Nation's children.

I ask my colleagues to vote for this important piece of legislation, which is bipartisan, and I reserve the balance of my time.

Mrs. CHRISTENSEN. Mr. Speaker, I yield myself such time as I may consume.

Mr. Speaker, I rise in strong support of S. 2154, the Emergency Medical Services for Children Reauthorization Act of 2014.

Established 30 years ago this year, the Emergency Medical Services for Children program has supported improvements to pediatric emergency care in all U.S. States, territories, and freely associated States. EMSC grant programs help assess emergency systems and implement quality improvement measures, improve services in